BUD
MCID: BRL010
MIFTS: 54

Buruli Ulcer (BUD)

Categories: Genetic diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Buruli Ulcer

MalaCards integrated aliases for Buruli Ulcer:

Name: Buruli Ulcer 58 77 54 56 45 17 74
Buruli Ulcer, Susceptibility to 58 30 13 6 41
Buruli Ulcer Disease 12 54 15
Mycobacterium Ulcerans, Susceptibility to 58
Mycobacterium Ulcerans 58
Bairnsdale Ulcer 12
Daintree Ulcer 12
Searle's Ulcer 12
Mossman Ulcer 12
Searl Ulcer 12
Bud 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050456
OMIM 58 610446
MeSH 45 D054312
NCIt 51 C84604
SNOMED-CT 69 15845006
ICD10 34 A31.1
UMLS 74 C0085568

Summaries for Buruli Ulcer

OMIM : 58 Buruli ulcer is an infectious disease prevalent in many tropical and subtropical regions caused by infection with Mycobacterium ulcerans. It is the third most frequent mycobacterial disease in humans worldwide, after tuberculosis (607948) and leprosy (246300). Lesions are most common on exposed parts of the body, especially the limbs. Buruli ulcer derives its name from a county in Uganda, East Africa, north of Kampala, where the disease was found in the late 1950s in hundreds of people living near marshes and riverine areas near the Nile River (Clancey et al., 1961; Barker, 1971). The disease was first described in the medical literature in 1948 in a report on patients in Australia (MacCallum et al., 1948). Patients have also been reported from tropical areas in Latin America and Asia (Stienstra et al., 2006; van der Werf et al., 2005). (610446)

MalaCards based summary : Buruli Ulcer, also known as buruli ulcer, susceptibility to, is related to leprosy 3 and bacterial infectious disease, and has symptoms including nodule An important gene associated with Buruli Ulcer is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and Immune response NFAT in immune response. The drugs Rifampicin and Streptomycin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and testes, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin or located in subcutaneous tissue, has material basis in Mycobacterium ulcerans, which could be transmitted by insects. The bacterium produces a toxin, named mycolactone, which causes subcutaneous fat necrosis and inhibits an immune response. The infection has symptom nodule, which is a painless, mobile swelling in the skin.

Wikipedia : 77 Buruli ulcer is an infectious disease caused by Mycobacterium ulcerans. The early stage of the infection... more...

Related Diseases for Buruli Ulcer

Diseases related to Buruli Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 30.7 IFNG IL10 SLC11A1
2 bacterial infectious disease 30.5 IFNG IL10 SLC11A1
3 hemorrhagic fever 30.0 CD40LG IFNG IL10
4 schistosomiasis 29.7 CD40LG IFNG IL10 IL4
5 allergic contact dermatitis 29.7 IFNG IL10 IL4
6 contact dermatitis 29.7 IFNG IL10 IL4
7 aspergillosis 29.6 IFNG IL10 IL4
8 pulmonary tuberculosis 29.4 IFNG IL10 IL4 SLC11A1
9 mycobacterium tuberculosis 1 29.4 IFNG IL10 IL4 SLC11A1
10 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 28.8 CD40LG IFNG IL10 IL4 WAS
11 renal hypodysplasia/aplasia 1 11.4
12 bronchogenic cyst 11.3
13 cephalic disorders 11.2
14 solitary median maxillary central incisor 11.0
15 incisors, fused mandibular 11.0
16 thiourea tasting 11.0
17 liebenberg syndrome 11.0
18 hyperinsulinemic hypoglycemia, familial, 2 11.0
19 optic papillitis 11.0
20 tongue disease 11.0
21 colorectal cancer 10.5
22 mycobacterium marinum 10.5
23 cephalosporin allergy 10.4 IFNG IL10
24 adenocarcinoma 10.4
25 campylobacteriosis 10.4 IFNG SLC11A1
26 chronic graft versus host disease 10.4 IFNG IL10
27 benign childhood occipital epilepsy, gastaut type 10.4
28 idiopathic achalasia 10.4 IL10 LOC111365141
29 clonorchiasis 10.3 IFNG IL10
30 tuberculoid leprosy 10.3 IFNG IL10
31 fungal meningitis 10.3 IFNG IL10
32 stomatitis 10.3
33 multicentric castleman disease 10.3 IFNG IL10
34 extrapulmonary tuberculosis 10.3 IFNG IL10 SLC11A1
35 osteomyelitis 10.3
36 testicular disease 10.3 IFNG IL10 SLC11A1
37 chronic active epstein-barr virus infection 10.3 IFNG IL10
38 lymphadenitis 10.3 IFNG IL10 SLC11A1
39 human immunodeficiency virus type 1 10.3
40 african tick-bite fever 10.3 CD40LG IFNG
41 oral squamous cell carcinoma 10.3
42 peanut allergy 10.2 IFNG IL10
43 plasmodium falciparum malaria 10.2 HBB IFNG IL10
44 ascaridiasis 10.2 IL10 NELFCD
45 squamous cell carcinoma 10.2
46 fascioliasis 10.2 IFNG IL10
47 influenza 10.2
48 tropical endomyocardial fibrosis 10.2 IL10 IL4
49 endomyocardial fibrosis 10.2 IL10 IL4
50 iron overload in africa 10.2 HBB SLC11A1

Graphical network of the top 20 diseases related to Buruli Ulcer:



Diseases related to Buruli Ulcer

Symptoms & Phenotypes for Buruli Ulcer

Clinical features from OMIM:

610446

Symptoms:

12
  • nodule

MGI Mouse Phenotypes related to Buruli Ulcer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ATF4 IFNG IL10 IL4 SLC11A1 WAS
2 endocrine/exocrine gland MP:0005379 9.17 ATF4 CD40LG IFNG IL10 IL4 SEC61A1

Drugs & Therapeutics for Buruli Ulcer

Drugs for Buruli Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifampicin Approved Phase 2, Phase 3,Phase 3,Not Applicable 13292-46-1 5381226 5458213
2
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 57-92-1 19649
3
Clarithromycin Approved Phase 2, Phase 3,Phase 3 81103-11-9 84029
4 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Not Applicable
5 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Not Applicable
6 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable
7 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Not Applicable
8 Cytochrome P-450 CYP3A Inducers Phase 2, Phase 3,Phase 3,Not Applicable
9 Antitubercular Agents Phase 2, Phase 3,Phase 3,Not Applicable
10 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 3
11 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3,Phase 3
12
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
13 Antimalarials Phase 2
14 Antiparasitic Agents Phase 2
15 Antiprotozoal Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA Completed NCT00321178 Phase 2, Phase 3 SR4 - switch to CR4
2 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
3 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
4 Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer Unknown status NCT02153034
5 Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics Unknown status NCT01432925 Not Applicable
6 Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia Recruiting NCT03683745

Search NIH Clinical Center for Buruli Ulcer

Cochrane evidence based reviews: buruli ulcer

Genetic Tests for Buruli Ulcer

Genetic tests related to Buruli Ulcer:

# Genetic test Affiliating Genes
1 Buruli Ulcer, Susceptibility to 30 SLC11A1

Anatomical Context for Buruli Ulcer

MalaCards organs/tissues related to Buruli Ulcer:

42
Skin, Bone, Testes, Breast, Endothelial, T Cells, Whole Blood

The Foundational Model of Anatomy Ontology organs/tissues related to Buruli Ulcer:

20
Skin Or

Publications for Buruli Ulcer

Articles related to Buruli Ulcer:

(show top 50) (show all 462)
# Title Authors Year
1
Comparison of Mycobacterium ulcerans (Buruli ulcer) and Leptospira sp. (Leptospirosis) dynamics in urban and rural settings. ( 30615683 )
2019
2
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. ( 30689630 )
2019
3
The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model. ( 30705268 )
2019
4
Mycobacterium ulcerans Population Genomics To Inform on the Spread of Buruli Ulcer across Central Africa. ( 30728280 )
2019
5
Confirmed Case of Buruli Ulcer, Senegal, 2018. ( 30789331 )
2019
6
The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. ( 30870426 )
2019
7
Decrease in Mycobacterium ulcerans disease (Buruli ulcer) in the Lalo District of Bénin (West Africa). ( 30871489 )
2019
8
Microdeletion on chromosome 8p23.1 in a familial form of severe Buruli ulcer. ( 29708969 )
2018
9
A severe case of <em>Mycobacterium ulcerans</em> (Buruli ulcer) osteomyelitis requiring a below-knee amputation. ( 29642809 )
2018
10
Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016. ( 29870529 )
2018
11
Buruli ulcer. Review of a neglected skin mycobacterial disease. ( 29343539 )
2018
12
A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans. ( 29712992 )
2018
13
The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia - Remains similar despite changing geographic distribution of disease. ( 29554096 )
2018
14
Surgery for Buruli ulcer in the antibiotic era. ( 29605497 )
2018
15
Report of a series of 82 cases of Buruli ulcer from Nigeria treated in Benin, from 2006 to 2016. ( 29522516 )
2018
16
Developing a Buruli ulcer community of practice in Bankim, Cameroon: A model for Buruli ulcer outreach in Africa. ( 29584724 )
2018
17
Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. ( 29605498 )
2018
18
Molecular detection of Mycobacterium ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of maritime region in Togo. ( 29782522 )
2018
19
Implementation of a decentralized community-based treatment program to improve the management of Buruli ulcer in the Ouinhi district of Benin, West Africa. ( 29529087 )
2018
20
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans. ( 29237707 )
2018
21
Perceived causes and risk factors of Buruli ulcer among patients at Agogo Presbyterian hospital in Ashanti Region of Ghana. ( 29361986 )
2018
22
Comparative genomics shows<i>Mycobacterium ulcerans</i>migration and expansion has preceded the rise of Buruli ulcer in south-eastern Australia. ( 29439984 )
2018
23
Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited. ( 29538643 )
2018
24
Subcutaneous Granulomatous Inflammation due to Basidiobolomycosis: Case Reports of 3 Patients in Buruli Ulcer Endemic Areas in Benin. ( 29545962 )
2018
25
Risk factors for Mycobacterium ulcerans infection (Buruli Ulcer) in Togo a98 a case-control study in Zio and Yoto districts of the maritime region. ( 29351741 )
2018
26
<i>In Silico</i> Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. ( 29954088 )
2018
27
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 29642808 )
2018
28
Diagnostic Accuracy of Clinical and Microbiological Signs in Patients with Skin Lesions Resembling Buruli Ulcer in an Endemic Region. ( 29538642 )
2018
29
Perception and incidence of Buruli ulcer in Ogun State, South West Nigeria: intensive epidemiological survey and public health intervention recommended. ( 30050630 )
2018
30
Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease. ( 30055020 )
2018
31
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 30071818 )
2018
32
Improving clinical and epidemiological predictors of Buruli ulcer. ( 30080870 )
2018
33
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. ( 30102705 )
2018
34
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). ( 30136733 )
2018
35
Surgery for Buruli ulcer in the antibiotic era. ( 30152360 )
2018
36
Challenges associated with the treatment of Buruli ulcer. ( 30168876 )
2018
37
Implementing active community-based surveillance-response system for Buruli ulcer early case detection and management in Ghana. ( 30208037 )
2018
38
The association of rainfall and Buruli ulcer in southeastern Australia. ( 30222751 )
2018
39
Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011-2016. ( 30334704 )
2018
40
Buruli ulcer in southern Côte D'ivoire: dynamic schemes of perception and interpretation of modes of transmission. ( 30376901 )
2018
41
Buruli Ulcer: a Review of the Current Knowledge. ( 30460172 )
2018
42
Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. ( 30556580 )
2018
43
Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. ( 30559131 )
2018
44
Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. ( 30560872 )
2018
45
Draft Genome Sequence of Mycobacterium ulcerans S4018 Isolated from a Patient with an Active Buruli Ulcer in Benin, Africa. ( 28450515 )
2017
46
Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. ( 28410412 )
2017
47
Evidences of the Low Implication of Mosquitoes in the Transmission of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer. ( 28932250 )
2017
48
Mycobacterium ulcerans DNA in Bandicoot Excreta in Buruli Ulcer-Endemic Area, Northern Queensland, Australia. ( 29148373 )
2017
49
Assessment of health care workers' knowledge, attitude and risk perception of Buruli ulcer disease in Southern Nigeria. ( 28957473 )
2017
50
Total Syntheses of Mycolactone A/B and its Analogues for the Exploration of the Biology of Buruli Ulcer. ( 29289244 )
2017

Variations for Buruli Ulcer

ClinVar genetic disease variations for Buruli Ulcer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh37 Chromosome 2, 219259732: 219259732
2 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh38 Chromosome 2, 218395009: 218395009

Expression for Buruli Ulcer

Search GEO for disease gene expression data for Buruli Ulcer.

Pathways for Buruli Ulcer

Pathways related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CD40LG HBB IFNG IL10 IL4 SEC61A1
2
Show member pathways
12.43 CD40LG IFNG IL10 IL4
3 12.35 CD40LG IFNG IL10 IL4
4
Show member pathways
12.01 CD40LG IFNG IL10 IL4
5 11.79 IFNG IL10 IL4
6
Show member pathways
11.76 CD40LG IFNG IL10 IL4 WAS
7 11.63 IFNG WAS WASL
8 11.59 IFNG IL10 IL4
9
Show member pathways
11.55 CD40LG IFNG IL4
10 11.5 IFNG IL10 IL4
11 11.43 CD40LG IL10 IL4
12 11.24 IFNG IL10 IL4
13 11.11 HBB IFNG IL10
14 11.02 CD40LG IFNG IL4
15 10.9 IFNG IL10 IL4
16 10.75 IFNG IL10 IL4
17 10.61 CD40LG HBB IFNG IL10

GO Terms for Buruli Ulcer

Cellular components related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin cortical patch GO:0030479 8.62 WAS WASL

Biological processes related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.93 ATF4 IL10 IL4 SLC11A1 WAS WASL
2 regulation of signaling receptor activity GO:0010469 9.86 CD40LG IFNG IL10 IL4
3 positive regulation of gene expression GO:0010628 9.84 ATF4 IFNG IL4 SLC11A1
4 B cell differentiation GO:0030183 9.61 CD40LG IL10 IL4
5 positive regulation of interleukin-12 production GO:0032735 9.57 CD40LG IFNG
6 response to interferon-gamma GO:0034341 9.55 SEC61A1 SLC11A1
7 actin filament-based movement GO:0030048 9.52 WAS WASL
8 defense response to protozoan GO:0042832 9.51 IL10 SLC11A1
9 actin polymerization or depolymerization GO:0008154 9.49 WAS WASL
10 positive regulation of actin nucleation GO:0051127 9.48 WAS WASL
11 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.4 WAS WASL
12 positive regulation of MHC class II biosynthetic process GO:0045348 9.37 IL10 IL4
13 actin cortical patch assembly GO:0000147 9.32 WAS WASL
14 actin cortical patch localization GO:0051666 9.26 WAS WASL
15 regulation of isotype switching GO:0045191 9.16 IL10 IL4
16 immune response GO:0006955 9.1 CD40LG IFNG IL10 IL4 SLC11A1 WAS
17 type 2 immune response GO:0042092 8.96 IL10 IL4

Molecular functions related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase regulator activity GO:0030695 8.96 WAS WASL
2 cytokine activity GO:0005125 8.92 CD40LG IFNG IL10 IL4

Sources for Buruli Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....